Is There a Lyme Disease Vaccine for Humans?

No Lyme disease vaccine is currently available for humans, but one came close to market two decades ago and a new candidate is in late-stage clinical trials. The original vaccine, LYMErix, was approved in 1998 and then pulled from shelves in 2002 after public fears about side effects cratered demand. Now Pfizer and the Austrian biotech Valneva are developing VLA15, a next-generation version designed to work against far more strains of the bacteria that cause Lyme disease, and early results look promising. The story of why we still lack a human Lyme vaccine, and when we might finally get one, involves science, economics, and a public relations cautionary tale that vaccine developers are still trying to learn from.

The Vaccine We Had and Lost

LYMErix, made by what was then SmithKline Beecham, was the first and so far only Lyme disease vaccine licensed for human use. It targeted a protein called outer surface protein A (OspA) on the Borrelia burgdorferi bacterium that causes Lyme disease. In a large clinical trial, the vaccine’s efficacy after two doses was about 49 percent, but after a third dose it jumped to 76 percent against confirmed Lyme disease and was even better at preventing the kind of silent infections that show no symptoms.¹ The FDA approved it in late 1998, and for a brief window, Americans living in tick-heavy areas could actually get vaccinated.

The vaccine worked through a clever mechanism. OspA is expressed by Borrelia while the bacteria sit in the tick’s gut, before the tick bites a person. When someone vaccinated was bitten, their anti-OspA antibodies were ingested by the tick along with the blood meal, killing the bacteria inside the tick before they could ever reach the human host. Research in mice confirmed that ticks feeding on vaccinated animals had sharply reduced levels of the pathogen.²

That mechanism, while effective, meant LYMErix was an unusual vaccine. It did not train the immune system to fight an active infection the way most vaccines do. Instead, it essentially treated the tick as the battleground. This distinction may have contributed to public confusion about what the vaccine could and could not do.

Why LYMErix Disappeared

Almost immediately after LYMErix hit the market, reports of joint pain and arthritis-like symptoms surfaced among some recipients. Lawsuits followed. Media coverage amplified the fear. Anti-vaccine advocacy groups at the time seized on the story. The reality, though, was more complicated than the headlines suggested. The FDA reviewed the available post-market safety data and found insufficient evidence to support a causal link between the vaccine and the reported adverse effects. The agency continued to permit its use.³

It did not matter. Public perception had already turned against the product. Sales collapsed, and in February 2002, GlaxoSmithKline (which had absorbed SmithKline Beecham) pulled LYMErix from the market, citing poor commercial performance rather than any confirmed safety problem.³ It remains one of the clearest examples of a safe, effective vaccine being undone not by the science but by the public’s perception of risk. Researchers and public health officials have since studied the episode as a cautionary tale about how negative media coverage and limited awareness of a vaccine’s benefits can sink even a well-supported product.

VLA15 and the Push for a New Vaccine

The most advanced vaccine candidate right now is VLA15, jointly developed by Valneva and Pfizer. Like LYMErix, it targets OspA, but with a major upgrade. LYMErix covered only a single OspA serotype, which meant it was really only useful against the single Borrelia species common in North America. VLA15 is designed to target six OspA serotypes, covering the range of Borrelia species responsible for Lyme disease across both North America and Europe.⁴ That geographic breadth matters because the Borrelia landscape in Europe and America looks quite different: most U.S. infections come from B. burgdorferi sensu stricto, while Europe’s cases are driven largely by B. afzelii and B. garinii, species absent from the United States.⁵

In a phase 1 trial in healthy adults, VLA15 proved safe and immunogenic. The higher-dose groups that received an aluminum-based adjuvant produced the strongest antibody responses, with measurable immune responses against all six OspA serotypes.⁶ Subsequent phase 2 booster studies in children and adolescents showed a tolerability profile consistent with earlier trials, with no vaccine-related serious adverse events observed.⁷ A large phase 3 efficacy trial has been underway, with the companies aiming for potential regulatory approval within the next few years. If it succeeds, VLA15 would be the first human Lyme vaccine in over two decades.

One lingering question is whether the LYMErix saga will haunt VLA15’s market reception. Researchers studying vaccine attitudes in one European survey found that roughly four in five respondents said they would vaccinate themselves or their child if a Lyme vaccine meeting their expectations became available, and trust in health experts was the single strongest predictor of willingness to get vaccinated.⁸ That is an encouraging signal, though actual uptake often falls short of stated willingness.

mRNA Vaccines Enter the Picture

The success of mRNA technology against COVID-19 inevitably raised the question: could a similar platform work for Lyme disease? Several research groups are now exploring this idea, and while none of these candidates are yet in human trials, the early mouse data are striking.

One team developed an mRNA vaccine encoding OspA wrapped in lipid nanoparticles, the same delivery vehicle used in the Pfizer and Moderna COVID shots. In mice, the mRNA version produced significantly higher antibody levels than a traditional protein-based OspA vaccine and even outperformed a licensed canine Lyme vaccine. More importantly, mice that received the mRNA vaccine were completely protected from Borrelia transmission during tick feeding.⁹

Another group took a different tack, targeting a protein called OspC instead of OspA. OspC is expressed by the bacterium at a different stage of infection and comes in many subtypes. The team built a polyvalent mRNA vaccine encoding five common OspC types. It protected mice against strains expressing three of those five types, with higher doses improving coverage against a fourth. The work is early-stage but represents the first demonstration that an OspC-targeted mRNA vaccine can actually work.¹⁰ OspC is interesting because its universal presence across Borrelia strains and high ability to provoke an immune response make it a natural candidate for a next-generation approach.¹¹

The mRNA platform has some theoretical advantages here. Manufacturing can be updated relatively quickly if new Borrelia strains emerge or if the vaccine needs to cover additional variants. Whether these laboratory results will translate into real-world human protection is still unknown, but the pipeline now has more diversity than at any point in Lyme vaccine history.

Vaccinating Against the Tick Itself

One of the more creative strategies under investigation does not target Borrelia at all. Instead, it targets the tick. Researchers at Yale and elsewhere have developed mRNA vaccines encoding proteins found in tick saliva, with the goal of training the host’s immune system to recognize a tick bite the moment it happens. In guinea pig experiments, animals vaccinated with a cocktail of 19 tick salivary proteins developed visible redness at the bite site almost immediately after ticks attached. The ticks fed poorly, detached early, and weighed far less than usual. The upshot was that Borrelia transmission was blocked, not because the vaccine killed the bacteria, but because the tick could not complete its blood meal.¹²

This concept draws on a natural phenomenon called acquired tick immunity. Animals that have been repeatedly bitten by ticks often develop a resistance to subsequent bites. The immune system learns to react to specific salivary proteins, creating inflammation that makes it harder for the tick to feed. Researchers have been working to identify exactly which proteins trigger this rejection response. One study fractionated tick saliva and identified 24 proteins associated with inducing tick immunity, which could serve as vaccine targets.¹³

The appeal of an anti-tick vaccine is that it could theoretically protect against multiple tick-borne diseases at once, since the protection mechanism does not depend on the specific pathogen the tick is carrying. A tick that cannot feed cannot transmit anything. The practical redness at the bite site also acts as a built-in alert system, telling the person they have been bitten and should check the area. Whether this approach will be effective in humans, who generally lack the robust acquired tick immunity seen in guinea pigs, remains an open question.

Vaccinating the Mice Instead of the People

Borrelia circulates in nature primarily through a cycle between ticks and small mammals, especially white-footed mice. If you could vaccinate those mice, you could potentially break the transmission cycle at its source and reduce the number of infected ticks in the environment without needing to vaccinate a single human.

This is not just a thought experiment. Researchers have developed oral bait vaccines containing OspA that can be distributed in the wild. When white-footed mice ate the vaccine-laced bait, they developed systemic antibody responses against OspA. In challenge experiments, these vaccinated mice were protected from Borrelia infection when bitten by ticks, and the ticks that fed on them were cleared of the spirochete.¹⁴ A separate effort confirmed that a bait-delivered OspA vaccine both decreased the ability of uninfected larval ticks to pick up the bacterium from mice and reduced transmission from infected ticks to the mice.¹⁵

Reservoir-targeted vaccines face their own challenges, including the logistics of distributing bait over large areas, ensuring enough of the mouse population eats it, and sustaining the effect year after year. But the approach has attracted interest as a complement to human vaccination, particularly in communities where Lyme risk is high and people may be reluctant to vaccinate themselves.

The Cost-Effectiveness Problem

Even when a Lyme vaccine exists and works, a harder question follows: who should get it, and is it worth the cost? Unlike childhood vaccines that prevent common, serious diseases, Lyme disease is geographically concentrated and treatable with antibiotics if caught early. That means the value of vaccination depends heavily on where you live and how likely you are to be bitten by an infected tick.

Economic analyses of the original LYMErix vaccine found that at the average national incidence of Lyme disease, vaccination was expensive relative to the benefit. One analysis estimated roughly $1.6 million per case averted when boosters were given for a decade, at the very low national average incidence. But in areas where about 1 percent of residents contracted Lyme annually, the figure dropped to around $10,000 per case averted.¹⁶ A separate analysis found that vaccinating residents of endemic areas with a 1-percent annual risk averted about 200 cases of Lyme disease per 10,000 people over ten years.¹⁷ The general consensus was that broad population-level vaccination made less sense than targeting people at elevated individual risk, such as those who spend significant time outdoors in endemic areas.¹⁸

These analyses were done for LYMErix at late-1990s prices. A new vaccine with broader coverage, potentially different dosing schedules, and application to both European and American markets could shift the math. Still, the underlying issue persists: Lyme vaccination is likely to be most justifiable for people in specific geographic pockets and occupational groups rather than for the general population.

What You Can Do Right Now

Without a licensed vaccine, prevention currently comes down to personal measures: wearing treated clothing, using repellents, performing tick checks, and showering after outdoor activity. For people who find an attached tick and are worried about Lyme, there is one well-studied pharmaceutical option. A single dose of doxycycline given within 72 hours of removing an engorged deer tick reduced the risk of developing the telltale erythema migrans rash by about 87 percent in a randomized trial.¹⁹ This approach is endorsed by many physicians in high-risk areas and has been shown to be effective in both the United States and Europe.²⁰

Doxycycline prophylaxis is not a substitute for a vaccine, since you have to know you were bitten, seek care quickly, and the antibiotic does cause nausea in a meaningful fraction of people who take it. But for now, it is the closest thing to a pharmacological safety net that exists.

Challenges a New Vaccine Still Faces

Designing a phase 3 trial for a Lyme vaccine is inherently complicated. Lyme disease is seasonal, regionally concentrated, and diagnosed through a combination of clinical findings and lab tests that are not always straightforward. Researchers who conducted the original LYMErix trials documented the logistical headaches involved: recruiting enough participants in endemic areas, following them through multiple tick seasons, and adjudicating cases where the diagnosis was uncertain.²¹ Early studies of LYMErix in children showed that side effects like injection-site soreness, headache, and fatigue were more common in the vaccine group than the placebo group, though they were mostly mild and lasted only a few days.²² Those are the kinds of routine reactogenicity findings that would normally not raise concern, but after the LYMErix backlash, manufacturers are acutely aware that even ordinary side effects can be weaponized in public discourse.

There is also the booster question. OspA-based vaccines appear to require periodic boosters to maintain protective antibody levels. If annual or biannual boosters are needed, that has implications for both cost-effectiveness and patient compliance. Some of the mRNA candidates under development could potentially address this by generating stronger or more durable immune responses, but that has not yet been demonstrated in human studies.

The political and cultural landscape around vaccination has shifted since 2002 as well. On one hand, COVID-19 made the general public more familiar with vaccine development timelines and mRNA technology. On the other, vaccine hesitancy has intensified in certain communities. How these crosscurrents will affect the reception of a Lyme vaccine is hard to predict. The Polish survey data showing that over 80 percent of respondents considered a Lyme vaccine necessary suggests demand exists in areas where the disease is common, but acceptance will vary by region, age, and political context.

The Canine Comparison

Here is an irony that frustrates many Lyme disease advocates: dogs can get vaccinated against Lyme disease right now, and have been able to for years. Several licensed canine Lyme vaccines are on the market, most of them also targeting OspA. They are widely used in endemic regions and considered a routine part of veterinary care for dogs that spend time outdoors in tick-heavy areas. The fact that a Lyme vaccine exists for pets but not for people speaks less to scientific barriers than to regulatory and commercial ones. The bar for veterinary vaccine approval is lower, the liability landscape is different, and the market dynamics are simpler. No class-action lawsuits followed the canine vaccines.

For researchers, the canine vaccines have served as a useful proof of concept. The mRNA OspA vaccine study mentioned earlier actually used a licensed canine Lyme vaccine as one of its comparison groups and showed the mRNA version outperformed it in generating antibodies in mice.⁹ If nothing else, the existence of successful canine vaccines is a standing reminder that the OspA approach works biologically. The obstacle to a human Lyme vaccine has always been more about market confidence, regulatory caution, and public perception than about the underlying science.